Form 4: ResMed CEO Michael Farrell Executes Option and Sells Shares Under 10b5-1 Plan

ResMed's CEO, Michael J. Farrell, exercised stock options and sold shares of ResMed Common Stock on October 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 7, 2024, Michael J. Farrell, the CEO of ResMed Inc., executed options to acquire 14,683 shares of ResMed Common Stock at a price of $84.98 per share.
• Simultaneously, Farrell sold 14,683 shares of ResMed Common Stock at a weighted average price of $231.9149, with individual sales prices ranging from $230.66 to $234.70.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on January 31, 2024.
• Following these transactions, Farrell directly owns 464,169 shares of ResMed Common Stock.
• Farrell also indirectly owns 4,090 shares through the Lisette and Michael Farrell Family Trust and an unspecified amount through the Lisette and Michael Farrell Foundation.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are part of a pre-planned trading strategy, and there's no indication of unusual activity or concern.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, which is generally viewed as a transparent and compliant way for insiders to trade company stock.

Negatives

• The sale of shares by the CEO, even under a 10b5-1 plan, could be perceived negatively by some investors, although it's a common practice.

Risks

• While the 10b5-1 plan provides a framework, significant insider selling could still create short-term price volatility.

Industry Context

Insider transactions are a common occurrence in publicly traded companies, and the use of Rule 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information. Investors often monitor these filings to gauge management's sentiment and confidence in the company's future prospects.

Comparison to Industry Standards

• ResMed's insider trading activity is similar to other large-cap medical device companies such as Medtronic and Stryker, where executives periodically exercise options and sell shares for personal financial planning.
• The use of a 10b5-1 plan aligns with best practices in corporate governance, as seen in companies like Johnson & Johnson and Abbott Laboratories, which also utilize these plans to manage insider trading.

Stakeholder Impact

• The transactions could have a minor short-term impact on shareholders due to the sale of shares, but the existence of a 10b5-1 plan mitigates concerns about insider information.

Key Dates